Immuno-chemotherapy in Metastatic Renal Cell Carcinoma: Long-Term Results from the Rambam and Linn Medical Centers, Haifa, Israel

References

• Keller, JW, McCune CS, Saharabudhe DM. Urological and male genital cancer. In: Rubin P, ed. Clinical Oncology 7t5 ed. Philadelphia: WB Saunders, 1993, Chapter 23.
   Google Scholar
• Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. Urology 2000; 55: 36–40
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Radical nephrectomy plus interferon-alpha-based immunother-apy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966–70.
   Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al: Nephrectomy followed by interfer-on alfa-2b compared with interferon alfa-2b alone for metasta-tic renal cell cancer. N Engl J Med 2001; 345: 1655–9.
   PubMed Web of Science ®Google Scholar
• Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 1993; 149: 19–21.
   PubMed Web of Science ®Google Scholar
• Kim B, Louie AC. Surgical resection following inter-leukin 2 therapy for metastatic renal cekk carcinoma prolongs remission. Arch Surg 1992; 127: 1343–9.
   PubMedGoogle Scholar
• Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cekk carcinoma. Ann Thorac Surg 1994; 57: 339–44.
   PubMed Web of Science ®Google Scholar
• Kierney PC, Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carci-noma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994; 1: 345–52.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Korfe A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interfer-on-a2b in advanced human malignancies. Lancet 1990; 335: 1509-12.
   Google Scholar
• Atzpodien J, Hanninen EL, Kirchner H, et al. Multi-institutional home-therapy trial of recombinant human inter-leukin-2 and interferon alfa-2 in progressive metastatic renal cekk carcinoma. J Clin Oncol 1995; 13: 497–501.
   PubMed Web of Science ®Google Scholar
• Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cekk carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19–25.
   PubMed Web of Science ®Google Scholar
• Gez E, Rubinov R, Gaitini D, Meretyk S et al: Interleukin-2, interferon-a, 5-fluorouracil and vinblastine in the treatment of metastatic renal cekk carcinoma. A prospective phase II study: The experience of Rambam and Linn Medical Centers 1996-2000. Cancer 2002; 95: 1644–9.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–16.
   PubMed Web of Science ®Google Scholar
• Irwin JO. Test of significance for differences between percentages based on small numbers. Metron 1935; 12: 83–94.
   Google Scholar
• Scheffe H. The Analysis of Variance. New York: John Wiley & Sons, 1995.
   Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–70.
   PubMedGoogle Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher R I, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cekk carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 16: 688–96.
   Google Scholar
• Facendola G, Locatelli MC, Pizzocaro G, et al. Subcutaneous administration of interleukin-2 and inteferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer 1995; 72: 1531–5.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Varthalitis J, Kostopoulou M, et al. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblas-tine in metastatic renal cell cancer. Oncology 1998; 55: 10–5.
   PubMed Web of Science ®Google Scholar
• Revaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alpha-2a and continuous infusion of fluorouracil in metastatic renal cekk carcinoma: a multicenter phase II trial. Group Francais de L'immunotherapie. J Clin Oncol 1998; 16: 2728–32.
   PubMed Web of Science ®Google Scholar
• Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP. Results of immuno-chemotherapy with inter-leukin-2, interferon-alpha2 and 5-fluorouracil in treatment of metastatic renal cell cancer. Eur Urol 1999; 35: 204–9.
   PubMed Web of Science ®Google Scholar
• Rogers E, Bredin H, Butler M, Corcoran M, Egan E, Fennelly J, et al. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the multicenter All Ireland Immunotherapy Study Group. Eur Urol 2000; 37: 37261–6.
   Google Scholar
• Escudier B, Szczylik C, Eisen T et al: randomized Phase III trial of the Raf Kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. ASCO 2005, Abstract #LB4510.
   Google Scholar
• Stadler WM. Targeted agents for treatment of advanced renal cell carcinoma. Cancer 2005: 104: 2323–33.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatic renal cekk carcinoma with a combina-tion of bevacizumab and erlotinib. J Clin Oncol 2005: 23: 7889–96.
   Google Scholar
• Rinit BI, Sosman JA and MotzertRJ. Therapy target at vascular endothelial growth factor in metastatic renal cekk car-cinoma: biology, clinical results and future development. BJU International 2005: 96: 286–90.
   Google Scholar
• Leibovich BC, Han KR, Bui MHT, et al. Scoring algo-rithm to predict survival after nephrectomy and immunothera-py in patients with metastatic renal cell carcinoma. Cancer 2003; 98: 2566–75.
   PubMed Web of Science ®Google Scholar